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ABSTRACT
Inflammatory breast cancer (IBC) is a virulent form of breast cancer, and 
novel treatment strategies are urgently needed. Immunohistochemical analysis of 
tumors from women with a clinical diagnosis of IBC (n = 147) and those with non-
IBC breast cancer (n = 2510) revealed that, whereas in non-IBC cases cytoplasmic 
cyclin E was highly correlated with poor prognosis (P < 0.001), in IBC cases both 
nuclear and cytoplasmic cyclin E were indicative of poor prognosis. These results 
underscored the utility of the cyclin E/CDK2 complex as a novel target for treatment. 
Because IBC cell lines were highly sensitive to the CDK2 inhibitors dinaciclib and 
meriolin 5, we developed a high-throughput survival assay (HTSA) to design novel 
sequential combination strategies based on the presence of cyclin E and CDK2. Using 
a 14-cell-line panel, we found that dinaciclib potentiated the activity of DNA-damaging 
chemotherapies treated in a sequence of dinaciclib followed by chemotherapy, 
whereas this was not true for paclitaxel. We also identified a signature of DNA repair–
related genes that are downregulated by dinaciclib, suggesting that global DNA repair 
is inhibited and that prolonged DNA damage leads to apoptosis. Taken together, 
our findings argue that CDK2-targeted combinations may be viable strategies in IBC 
worthy of future clinical investigation. 
INTRODUCTION
Inflammatory breast cancer (IBC) is the most 
aggressive subtype of breast cancer, accounting for 
2–5% of breast cancers in the United States but causing 
an estimated 10% of total breast cancer mortality. This 
mortality occurs despite the use of modern chemotherapy 
regimens given in the neoadjuvant setting including 
both anthracyclines and taxanes, followed by modified 
radical mastectomy and comprehensive post-mastectomy 
radiation [1–3]. This disproportional mortality and a 
low pathological complete response rate (of about 15% 
overall) indicate that the current treatment strategies 
for these patients are suboptimal, and more effective 
treatments are necessary [4]. One challenge in the current 
treatment of IBC is the lack of well-validated targets with 
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available drugs, along with an incomplete understanding 
of the molecular basis of the relative chemoresistance that 
characterizes many IBC tumors. Gene expression and 
genomic characterization of breast cancer have revealed 
that a number of molecular subtypes exist that not only 
describe different underlying biology and therapeutic 
vulnerabilities but also result in disparate clinical 
outcomes [5]. For example, hormone receptor–positive 
cancers (which are mostly luminal A/B by PAM50 gene 
expression) are known to have more indolent biology 
than do triple-negative breast cancers (TNBCs), of which 
80% are basal by PAM50 subtyping. Similar analyses of 
IBC samples by the World Consortium have confirmed 
the presence of all of these subtypes in IBC, albeit in a 
different distribution [6]. These results therefore have not 
uncovered a significant number of novel unique targets for 
evaluation in IBC. 
One potential novel treatment strategy being 
investigated by several groups, including ours, is targeting 
CDK2. This follows logically from our discovery of tumor-
specific isoforms of cyclin E that bind CDK2 more tightly 
and that promote its activity in a cell cycle–independent 
manner [7]. As a key regulator of the G1-S checkpoint, 
cyclin E acts as a potent oncogene driving aberrant 
proliferation. In addition to its role in regulating progression 
through the cell cycle, we have found additional oncogenic 
roles of cyclin E including centrosome reduplication, 
enhanced growth factor signaling, and increased cancer 
stem cell phenotypes [8–11]. 
Previously we have shown that overexpression of 
cyclin E in breast cancer patient samples is associated with 
poor prognosis [12]. In addition to overexpression of full-
length cyclin E protein, tumors express low-molecular-
weight isoforms, termed LMW-E, which are generated 
via amino terminus cleavage of full length cyclin E by 
the serine protease neutrophil elastase [7]. These LMW-E 
isoforms are sequestered in the cytoplasm where they 
regulate additional substrates not usually regulated by 
nuclear cyclin E/CDK2 complexes [13]. To understand 
the biological roles of LMW-E, we previously generated 
transgenic mouse models of mammary tumors driven by 
LMW-E in a setting of CDK2 proficiency or deficiency. 
CDK2 expression was necessary for mammary tumors 
driven by LMW-E, suggesting that cyclin E may serve 
as a biomarker for the use of CDK2 inhibitors [14]. In 
the mouse tumor model, roscovitine and meriolin 5 both 
significantly delayed the development of tumors. On 
the basis of these results, we hypothesized that breast 
cancer cells overexpressing cyclin E (including LMW-E) 
may be sensitive to CDK2 inhibitors either alone or in 
combination with other agents. We have recently reported 
that LMW-E is a poor prognostic biomarker in breast 
cancer, further providing rationale for investigation of 
this pathway; however, previous patient cohorts did not 
include patients with IBC [15, 16]. In this study, we sought 
to examine the relevance of the cyclin E-CDK2 pathway 
in human IBC samples and design targeted combination 
treatments targeting this pathway.
Currently two classes of selective CDK inhibitors 
are being developed clinically. One class includes specific 
CDK4/6 inhibitors (such as palbociclib, ribociclib, and 
abemaciclib), which are being used in cancers that retain 
Rb-pathway functionality and/or amplification of CDK4 
or CDK6, such as ER-positive breast cancers, melanomas, 
and sarcomas [17, 18]. The other distinct class includes 
CDK inhibitors that are more selective for CDK1 and 
CDK2 as well as the transcriptional CDKs (CDK5, CDK7, 
and CDK9), and these drugs are being more widely studied 
in cancers including triple-negative breast cancer [19]. 
Dinaciclib (SCH727965) is a potent second-generation 
drug in this class that we have evaluated in both IBC and 
non-IBC breast cancer cell lines. 
We found that IBC cell lines are sensitive to 
dinaciclib and to meriolin 5, another CDK2 inhibitor [20]. 
Because combination therapy is needed for aggressive 
cancers such as IBC, we next screened combinations of 
dinaciclib with other chemotherapy agents currently used 
clinically for the treatment of breast cancer, using a high-
throughput cell survival assay we developed to examine 
pairs of drugs in both sequences to identify the most 
synergistic combinations to advance into preclinical and 
clinical trials. The expression of a panel of DNA repair 
genes following dinaciclib treatment in TNBC cell lines 
(IBC and non-IBC) significantly decreased. These results 
suggest that prolonged DNA damage as a consequence of 
decreased DNA repair may be the mechanism underlying 
the sequence-specific synergism with chemotherapies that 
cause DNA damage. 
RESULTS
Cyclin E expression and localization in IBC 
tumors
To establish the clinical relevance of cyclin E as a 
therapeutic target in IBC, we examined the expression 
and localization of cyclin E in IBC samples from 
patients who received treatment or had consults at MD 
Anderson Cancer Center, using our previously established 
immunohistochemical method that incorporates both 
nuclear and cytoplasmic staining, and we compared 
these results to those for a large cohort of 2510 patients 
with non-inflammatory breast cancer [15, 16]. Clinical 
and treatment characteristics of all patient cohorts 
are shown in Table 1. Tumors were scored for cyclin 
E as one of four phenotypes, based on intensity and 
localization (Figure 1A): phenotype 1 tumors did not 
express significant cyclin E in the nucleus or cytoplasm, 
phenotype 2 tumors expressed nuclear cyclin E, phenotype 
3 tumors expressed nuclear and cytoplasmic staining, 
and phenotype 4 tumors expressed cytoplasmic staining 
[16]. In our cohort of 2510 non-IBC patients, 11% of 
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Table 1: Clinical variables for patient samples
  Non-IBC (N = 2510) IBC (N = 147) P value
Age at diagnosis (year)   < 0.0001*
 Mean 61.1 49.8
 Median (Range) 62 (25–96) 49 (23–76)
 < 50, no. (%) 629 (25.1) 76 (51.7) < 0.0001
 > = 50, no (%) 1881 (74.9) 71 (48.3)
Tumor category, no (%)   < 0.0001^
 T1 1282 (51.2) 0
 T2 1182 (47.2) 0
 T3 23 (0.9) 0
 T4 15 (0.6) 147 (100)
 Unknown 8  
Nodal status, no. (%)   < 0.0001
 Negative 1533 (61.4) 0
 Positive 962 (38.6) 147 (100)
Chemotherapy, no (%) < 0.0001
 No 1672 (66.6) 0
Yes 838 (33.4) 147 (100)
Radiation therapy, no (%)   < 0.0001
No 1616 (64.4) 32 (21.8)
 Yes 894 (35.6) 115 (78.2)
Adjuvant Endocrine therapy, no (%)   0.02
No 1363 (54.3) 95 (64.6)
 Yes 1147 (45.7) 52 (35.4)
Stage, no. (%)   < 0.0001^
 I 1138 (45.3) 0
 II 1176 (46.8) 0
 III 190 (7.6) 131 (89.1)
 IV 0 16 (11.9)
 Unknown 6  
Tumor grade   < 0.0001^
I 324 (16.4) 0
 II 990 (49.9) 32 (22.2)
III 668 (33.7) 112 (77.8)
 Unknown 528 3
Estrogen receptor status < 0.0001^
 Negative 693 (28.1) 60 (45.1)
Positive (> 1% cutoff) 1772 (71.9) 73 (57.9)
 Unknown 45 14 
Progesterone receptor status < 0.0001^
 Negative 949 (38.5) 78 (58.6)
Positive (> 1% cutoff) 1514 (61.5) 55 (41.4)
 Unknown 47 14 
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the samples had no cyclin E staining, 28% had nuclear 
positivity, 23% had nuclear and cytoplasmic positivity, 
and 38% had cytoplasmic staining (Figure 1A, 1C). On 
the other hand, the distribution of nuclear and cytoplasmic 
cyclin E staining was very different in the IBC cohort, 
where we observed 100% positivity for cyclin E in all the 
samples examined. Only 13% of the IBC samples had only 
nuclear staining, whereas the remaining 87% were strongly 
positive for cytoplasmic cyclin E (48% had nuclear and 
cytoplasmic staining and 39% had cytoplasmic staining) 
(Figure 1B, 1C). 
Cytoplasmic staining of cyclin E in the non-IBC 
cases was significantly correlated with poor prognosis 
(P < 0.001, Figure 1D), whereas all patients in the IBC 
cohort had a poor outcome (Figure 1E), regardless of 
nuclear or cytoplasmic expression of cyclin E. These 
results suggest that expression of any cyclin E is likely 
to be an essential oncogenic driver for IBC pathogenesis, 
and we reason that the high frequency of overexpression 
makes this pathway an ideal target for therapy.
Targeting cyclin E in IBC and non-IBC cell lines
We next investigated whether treatment of IBC 
cell lines (SUM149 and KPL4) with CDK inhibitors is a 
viable therapeutic option. SUM149 is a BRCA1-deficient 
triple-negative IBC cell line, and KPL4 is a HER2-
overexpressing (but trastuzumab-resistant) cell line. These 
models were chosen as established models that grow well 
in 2-dimensional culture and at sufficiently low density 
for our long-term assays. Both established lines had high 
levels of full-length cyclin E, and SUM149 also expressed 
LMW-E isoforms and higher phospho-CDK2 (Thr160) 
expression compared with KPL4 (Figure 2A). 
Dinaciclib, a potent CDK2 inhibitor (as well as 
CDK1, CDK5, and CDK9 inhibitor) that is currently in 
clinical trials for several cancers, was used to target the 
cyclin E/CDK2 pathway. We compared the IBC cell line 
sensitivity to dinaciclib to that of a panel of 12 other 
breast cancer cell lines from all molecular subtypes 
including the Lehmann TNBC subtypes except for 
immunomodulatory (Supplementary Table 1 and 2) [21]. 
Dose-response analysis of dinaciclib indicated that all IBC 
and non-IBC breast cancer cell lines (with the exception 
of T47D) were highly sensitive to dinaciclib, with half 
maximal inhibitory concentration (IC
50
) values ranging 
from 4.24 nM to 18 nM following 24-hour treatment 
(Figure 2B, Supplementary Table 3). We also examined 
meriolin 5, a structurally distinct CDK2 inhibitor [20], and 
found that the IC
50
 values of meriolin 5 in both IBC cell 
lines were in the low nanomolar range (between 20 and 
80 nM) depending on treatment time and assay length; 
however, 72 hours of exposure was enough to cause 
maximal cytotoxicity (Figure 2C). Taken together, these 
results suggest that CDK2 is a valid target in IBC worth 
further consideration.
To determine whether dinaciclib induced apoptosis, 
we performed annexin V/PI staining and also counted the 
cell numbers as a function of days after drug treatment 
(day 3) and at 2 and 4 days after drug removal. We observed 
a dose-dependent increase in annexin V positive cells at 
both time intervals in both IBC cell lines, and cell death 
continued even after drug removal (Figure 2D). These 
results corresponded with the significantly decreased cell 
numbers at all concentrations of dinaciclib, supporting the 
conclusion that dinaciclib has direct cytotoxic activity in 
IBC cells (Figure 2E). Dinaciclib treatment also increased 
cleaved PARP and cleaved caspase 3, additional indicators 
of apoptosis. We also confirmed that Mcl1 is downregulated 
in response to dinaciclib treatment, consistent with previous 
findings in other systems (Figure 2F).
Combination treatment with CDK2 inhibitors in 
IBC
We next set out to identify treatment strategies to 
improve upon the activity of dinaciclib. To this end, we 
evaluated whether sequential combinations of dinaciclib 
and different classes of chemotherapy that are being used 
or have been used in breast cancer act in a synergistic 
manner. To do this in a high-throughput comprehensive 
way, we designed a 96-well plate format high-throughput 
survival assay (HTSA) [22]. This assay, which can be 
used for any adherent cell line, allows us to analyze 
HER2 status < 0.0001^
 Negative 2113 (85.3) 63 (61.2)
 Positive 365 (14.7) 40 (38.8)
Unknown/not tested 32 44 
Cyclin E phenotypes   < 0.0001
 1 267 (10.6) 0
 2 718 (28.6) 19 (12.9)
3 572 (22.8) 70 (47.6)
 4 953 (38) 58 (39.5)
*Wilcoxon rank-sum (Mann-Whitney) test; ^p value calculated after excluded unknown category. 
Oncotarget5www.impactjournals.com/oncotarget
the combination of two drugs added sequentially or 
concomitantly and to examine the survival fraction after 
an extended period of time in culture (12 days), similar 
to how a clonogenic assay is performed (Figure 3A). The 
drug concentrations used for these experiments are shown 
in Supplementary Tables 3–8. The survival fractions for 
each of the 24 pairs of drug A-B concentrations were 
calculated, and CalcuSyn software was used to derive 
combination indexes (CIs) for each using the Median 
Effect models described by Chou and Talalay [23]. The 
absolute value of the CIs determines the degree of synergy 
or antagonism of drug combinations, and we considered 
CIs below 0.9 to be synergistic and above 1.1 to be 
antagonistic. 
We focused on using both IBC cell lines to 
comprehensively investigate a combination of dinaciclib 
with chemotherapy drugs (epirubicin, carboplatin, etoposide, 
and paclitaxel) in both sequences. In SUM149 cells, we 
Figure 1: Cyclin E is overexpressed in IBC patient samples. Representative immunohistochemical images showing cyclin E 
staining phenotypes in (A) non-IBC and (B) IBC tumors. N = nuclear staining C = cytoplasmic staining, either present (+) or absent (–) 
(C) Comparison of the distribution of staining phenotypes in non-IBC versus IBC cohorts. P < 0.0001, chi-squared test. (D, E) Kaplan-
Meier survival plot showing the association between cyclin E staining (N and C and freedom-from-recurrence (FFR) for non-IBC cohort 
stratified by cyclin E phenotype regardless of hormone receptor/HER2 status. P < 0.0001. (E) Kaplan-Meier survival plot of non-IBC (D) 
and IBC (E) cohorts as a function of cyclin E phenotype. 
Oncotarget6www.impactjournals.com/oncotarget
Figure 2: CDK2 is a target in breast cancers including IBC. (A) Western blot of 13 breast cancer cell lines including IBC 
cells (SUM149 and KPL4) showing activation of cyclin E/CDK2 pathway particularly among TNBC lines. (B) IC
50
 values of dinaciclib 
(12 day assay) in 13 breast cancer cell lines.  Bars are color-coded by molecular subtype, with both basal-like subtypes combined and 
both mesenchymal subtypes combined. Asterisks refer to the two IBC cell lines. (C) IC
50
 values for IBC cell lines treated with meriolin 
5 for either 72 hours (left graph) or 24/48 hours and allowed to recover for 12 days prior to the MTT assay (right graph). (D) IBC cells 
(left panels, SUM149 cells; right panels KPL4 cells) were treated with indicated concentration of dinaciclib for 72 hours and subjected to 
Annexin V staining at the end of treatment or 72 hours post treatment. *P < 0.05 compared to 0 control. (E) IBC cells (left panels, SUM149 
cells; right panels KPL4 cells) were treated with indicated concentration of dinaciclib for 3, 5 and 7 days and subjected to cell proliferation 
assays. *P < 0.05 compared to DMSO control.  Error bars: standard deviation. (F) Western blot showing increase in apoptosis markers 
(cleaved caspase 3 and cleaved PARP), and downregulation of Mcl1. Densitometry analysis of cleaved PARP and caspase 3 are depicted in 
the graphs on the right.  β-actin serves as loading control for gels.
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found that dinaciclib followed by epirubicin, carboplatin, or 
etoposide demonstrated moderate to strong synergy, whereas 
the reverse sequence was either additive or less synergistic 
(Figure 3B and Supplementary Table 9). However, 
dinaciclib followed by paclitaxel was antagonistic in this cell 
line, while the reverse sequence was slightly synergistic. 
Paclitaxel acts as an anti-mitotic chemotherapy via 
tubulin polymerization and blocking depolymerization 
of microtubules, whereas the other three chemotherapy 
drugs tested all have DNA damage as a key mechanism of 
action (whether via direct DNA adducts or via inhibition 
of topoisomerase activity). We confirmed the result that 
dinaciclib followed by DNA-damaging chemotherapy is 
effective in KPL4 cells; unlike in SUM149 cells, however, 
in KPL4 cells the sequence did not matter as much to 
the synergism observed (Figure 3C). To confirm these 
results with a different CDK2 inhibitor, we used meriolin 
5 in place of dinaciclib and determined the combination 
synergism using the same HTSA method. Consistent 
with the previous result, meriolin 5 induced moderately 
strong synergy (CI = 0.62 for SUM149 and CI = 0.79 
for KPL4), whereas the reverse sequence was additive or 
antagonistic (CI = 0.93 for SUM149 and CI = 1.21 for 
KPL4) (Figure 3D).
Given that we observed that CDK inhibition 
potentiates DNA-damaging agents in IBC, we reasoned 
that dinaciclib may also act as a radiosensitizer if given 
prior to radiation. To investigate this, we adapted the 
HTSA to allow for radiation to be “drug B” and once again 
tested this combination in both IBC cell lines. SUM149 
cells received 1–6 Gy and KPL4 received 3–12 Gy 
of radiation after treatment with 10–20 nM dinaciclib. 
These results demonstrated that, as the dose of dinaciclib 
increased, so did the magnitude of synergy, starting from 
additivity at a low dose (10 nM) and showing strong 
synergy at 20 nM, the highest dose tested (Figure 3E). 
Predictors of synergism in IBC and non-IBC 
models
We next examined the generality of the sequence-
specific synergism of dinaciclib followed by different 
classes of chemotherapeutic agents in non-IBC cell lines. 
Molecularly, IBC cells are similar to subtype-matched 
non-IBC cells, and even within the TNBC subtypes, the 
distribution of subtypes among TNBC and TN-IBC is 
similar when applying the Lehmann classification [21]. 
We used a total of 14 cell lines from different subtypes for 
this analysis (Figure 4A). Using a cut-off of ≤ 0.9 to define 
synergy, we found five of the 14 cell lines (SUM149, 
HCC1937, BT549, MDA-MB-436, and MDA-MB-361) 
were synergistic when dinaciclib was “drug A” and 
epirubicin was “drug B,” and in all five lines the average 
CI was higher for the reverse sequence. Similarly for 
carboplatin as “drug B,” we found that eight of the 14 cell 
lines (SUM149, HCC1806, HCC1937, MDA-MB-468, 
BT549, MDA-MB-157, MDA-MB-436, and MCF7) 
showed even more synergy in general compared with 
epirubicin, and once again in all of these lines the average 
CI was higher for the reverse sequence (Supplementary 
Tables 9 and 10).
Since we examined the synergistic response of 
four different combination strategies in 14 different cell 
lines, we next set out to identify predictors of response. 
Specifically, we asked whether molecular subtype, p53 
status, or the ability of cells to arrest in G1 or G2/M 
could predict response to the combination of dinaciclib 
and chemotherapy. However, none of these factors 
provided any predictive value to the synergistic response 
(Supplementary Figure 2A–2C). For example, the 
majority of TNBC tumors (85%) and all TNBC cell lines 
examined in this study harbor a mutation in the TP53 
gene. It is plausible that loss of the G1 checkpoint as a 
result of p53 loss of function would poise tumor cells for 
subsequent G2 checkpoint-targeting agents. Given that 
our data shows that the mechanism of dinaciclib-induced 
synergy involves a widespread downregulation of DNA 
repair genes and master transcriptional regulators, it is 
unlikely for p53 status to be critical to synergy. However, 
when we analyzed the proportion of sub-G1 cells both 
after 48 hours of treatment and after 48 hours of recovery 
in fresh medium and stratified the cells by subtype, 
we found that both basal-like cell lines (SUM149 and 
MDA-MB-468) and one HER2+ cell line (SKBR3) had 
significant increases in sub-G1 following treatment, which 
increased in the 48-hour recovery set, suggesting that cell 
death continued to be induced even after drug removal 
(Figure 4B). 
Dinaciclib-induced DNA damage in the 
synergistic cell lines    
Because both radiation and chemotherapies such as 
epirubicin and carboplatin induce DNA damage, and DNA 
repair induction is necessary for cell survival [24–32], we 
next investigated whether dinaciclib treatment of cells (as a 
single agent) can also modulate DNA damage checkpoints 
to inhibit repair of chemotherapy-induced DNA damage. 
To this end, IBC and non-IBC cells were treated with 
10–30 nM dinaciclib and subjected to qRT-PCR with a 
panel of genes involved in DNA damage checkpoints (ATM, 
BARD1, BRCA1, BRCA2, FANCA, MDC1, MSH2, 
and RAD51) [24–32]. These genes are transcriptionally 
regulated by several transcription factors including c-Myc, 
E2F1, NF-κB, and STAT3, which we also examined. In 
both SUM149 and HCC1937 cells, we observed two 
patterns of gene expression: a subset was downregulated 
at all doses (ATM, BRCA1, BRCA2, MDC1), whereas the 
other genes (BARD1, FANCA, MSH2, RAD51) showed a 
biphasic response in that at low doses they were increased 
but at higher doses (sufficient for pronounced cell growth 
inhibition) the genes were downregulated (Figure 5A and 
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Figure 3: Novel combination strategies involving CDK2 inhibitors with chemotherapy/radiation. (A) Schematic for high-
throughput survival assay (HTSA). Cells are plated at pre-defined densities in 96-well plates 24 hours prior to beginning drug treatments. 
The two drugs (arbitrarily called drug A and drug B) are added 24 hours apart, with the medium changed on day 2 and every 48 hours 
there after. Drug A concentrations are IC25, IC50, and IC75, and drug B concentrations range from IC10 through IC60, of which there are eight 
combinations of doses per plate. The MTT assay is performed on day 12 as a readout of cell survival fraction. Survival fraction data are 
input into CalcuSyn software to generate combination indexes (CIs). (B, C) CI of sequential treatment of SUM149 cells (B) and KPL4 (C) 
with dinaciclib followed by the indicated chemotherapies (purple and maroon bars) or the indicated chemotherapies followed by dinaciclib 
(green and blue bars). Each dot represents one of the pairs of drug concentrations. Dotted lines represent the CI range of additivity (0.9–1.1), 
antagonism (> 1.1) or synergism (< 0.9). (D) CI of sequential combination treatment of meriolin 5 followed by epirubicin (purple bars) 
or epirubicin followed by meriolin 5 (green bars) in SUM149 and KPL4 cells. (E) CI of sequential combination treatment of dinaciclib 
followed by radiation (as “drug B”). SUM149 cells received 1, 2, 4, or 6 Gy of radiation, and KPL4 cells received 3, 6, 9, or 12 Gy of 
radiation. The dotted lines represent the CI range of additivity as described in panels B and C.
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Figure 4: Predictors of response to dinaciclib/combination treatment. (A) Heatmap of CIs representing a comprehensive 
14–cell line panel screen, using 4 different sequential drug combinations: dinaciclib (Dina) with either epirubicin (Epi) or carboplatin 
(Carbo) in both sequences. Blue indicates synergism and red indicates antagonism. (B) The indicated cells (color coded for each subtype) 
were treated with DMSO or 20 nM dinaciclib for 48 hours.  Cells were subjected to flow cytometry at the end of the treatment period of 
48 hours post treatment (+48 h Rec) to measure sub G1 population.
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Supplementary Table 11). These gene expression results 
held true for both 24 and 72 hours of dinaciclib treatment 
(Figure 5B and Supplementary Table 12). 
Examination of the transcriptional factors known to 
regulate the DNA repair genes among our signature did 
not show a consistent concomitant decrease in expression 
across both cell lines and time points (Figure 5A–5B). For 
example, after 24 hours of treatment, c-Myc and E2F1 
increased in SUM149, but only E2F1 remained elevated 
after 72 hours of treatment. STAT3 was more consistently 
downregulated in SUM149, and this correlates with the fact 
that the known STAT3 target gene MDC1 was also robustly 
downregulated under the same conditions. In HCC1937 
cells, c-Myc expression exhibited a biphasic response at 
both 24 and 72 hours, whereas E2F1 showed a biphasic 
response at the early time point but not at 72 hours. Once 
again STAT3 was most consistently downregulated in 
HCC1937 cells. The results indicate that expression of 
these factors may not reflect their activity; however, their 
target genes may be biomarkers of dinaciclib activity.
Because all of the DNA repair genes we examined 
were potently downregulated by 30 nM dinaciclib, we 
asked whether other G2/M arresting drugs also inhibit 
these pathways, or whether this signature is specific for 
dinaciclib. To examine this, we looked at three of the 
most differentially expressed genes from the dinaciclib-
regulated candidates (BRCA1, MDC1, and RAD51) 
in SUM149 cells that were treated with MLN8237. 
MLN8237 (alisertib), is an Aurora kinase A inhibitor that 
is known to induce G2 arrest [33]. As expected, even a 
high dose of MLN8237 (1 μM), which was sufficient to 
induce a similar degree of cell proliferation inhibition, did 
not downregulate any of the DNA repair genes, and in the 
case of RAD51 increased its expression (Figure 5C and 
Supplementary Table 13). Hence, the dinaciclib-regulated 
gene signature is drug specific and not merely an indicator 
of altered cell cycle.
One consequence of unrepaired DNA damage in 
cells that have already committed to undergo cell division 
is polyploidy, which may lead to mitotic catastrophe 
[34]. We examined the polyploid population of cells 
in both IBC cell lines as well as in MDA-MB-468 and 
MDA-MB-436 cells as examples of antagonistic and 
synergistic cell lines. Cells were treated with sequential 
combinations of dinaciclib and epirubicin, and then cells 
were either collected or allowed to recover for 48 hours 
before fixation. We observed a negative correlation 
(r2 = 0.74) in the magnitude of polyploidy after treatment 
with the average CI values for each cell line (Figure 5D). 
These results suggested that cells that underwent the most 
polyploidy were most likely to have a synergistic response 
to combination treatment.
DISCUSSION
This work for the first time identifies cyclin E as 
a biomarker for therapy in IBC. IBC currently lacks any 
targeted treatment strategies (apart from trastuzumab and 
pertuzumab for HER2-overexpressing tumors) and, due 
to its intrinsic aggressiveness, confers a poorer prognosis 
than other stage- and subtype-matched breast cancers. 
We found a universally high expression of cyclin E in a 
large cohort of IBC patient samples and demonstrated 
that the distribution of cyclin E immunophenotypes is 
distinct from that for our non-IBC cohort. In addition 
to the different distribution of subtypes in IBC, when 
we evaluated freedom-from-recurrence as a function of 
cyclin E phenotype, we found that cyclin E phenotype 
did not predict outcome in IBC, in contrast to the highly 
significant correlation between cytoplasmic cyclin E and 
poorer outcome in the non-IBC cohort. 
Previous work from our group has shown that 
cytoplasmic LMW-E has novel kinase-dependent 
functions outside of the cell cycle that contribute to its 
oncogenicity, for example, as a regulator of EMT and 
cancer stem-cell phenotypes [11]. IBC is characterized 
by an early invasive phenotype, whereby tumor cells 
invade lymphovascular spaces as emboli, which results in 
the prototypical manifestation of IBC as a red engorged 
breast, and high incidence of de novo metastatic disease. 
Our work suggests that cyclin E may be a driver of this 
unique biology in IBC, and therefore early targeting of 
this pathway may be beneficial, especially in patients with 
demonstrated intrinsic resistance to chemotherapy. There 
is an ever-increasing body of work linking the quiescent 
nature of cancer stem cells with drug resistance, including 
a recent report in IBC, which showed that the cancer 
stem cell population (CD44hi, CD24low cells) expresses 
high levels of cyclin E, and combined targeting of CDK2 
enhances response to chemotherapy [35]. However, this 
report used a very high dose of paclitaxel and concomitant 
treatment with a CDK2 inhibitor, versus our work which 
focuses on DNA damaging agents. 
Cyclin E is an attractive target in IBC for a number 
of reasons. Our data from patient samples indicated a high 
incidence of overexpression, making biomarker selection 
as a criterion for the clinical trial unnecessary. Given IBC 
patient volumes in any single center, the feasibility of a 
biomarker-selected trial is a challenge if only a portion of 
the overall potential population would be eligible for the 
trial based on a lower incidence of the biomarker. Second, 
cyclin E is clearly an oncogenic driver in breast cancer, and 
it influences a number of important phenotypes beyond 
cell cycle progression such as EMT and cancer stem cell 
enrichment, which are prominent factors in IBC as well. 
Third, there are clinically available agents that target the 
cyclin E/CDK2 complex. One of these agents, dinaciclib, 
has caused unexpected high toxicity in early clinical trials, 
mainly due to the high doses used. In the first-in-human 
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Figure 5: Dinaciclib inhibits multiple DNA repair pathways to induce synergism with DNA-damaging chemotherapy 
and induce polyploidy. (A, B) Heatmap depicting fold changes for expression of the indicated genes (as measured by qRT-PCR) in 
SUM149 (A) or HCC1937 (B) cells treated with 10–30 nM dinaciclib for 24 or 72 hours. Fold changes were compared within each time 
point, compared with DMSO control. The bottom row indicates cell number (as a percentage of control) for each condition, to correlate the 
magnitude of change in gene expression with cytotoxicity of the drug. (C) Heatmap depicting fold changes for expression of the indicated 
genes (as measured by qRT-PCR) in SUM149 cells treated with 1 μM MLN8237 for 24 or 72 hours. The cell number row was calculated 
similarly to A. (D) Cells were treated with sequentially with dinaciclib followed by epirubicin with or without a 48 hour recovery period 
and subjected to polyploid DNA content by FACS analysis. SUM149 (8 nM dinaciclib and 20 nM epirubicin), KPL4 (10 nM dinaciclib and 
15 nM epirubicin), MDA-MB-468 (18 nM dinaciclib and 5 nM epirubicin), and MDA-MB-436 (12.52 nM dinaciclib and 4 nM epirubicin). 
The average CI values for the dinaciclib-epirubicin combination are listed under each cell line bars. Bottom panel: Concordance of CI and 
polyploidy as depicted in the logistic regression analysis graph. Error bars represent standard deviation based on two or three independent 
experiments.
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phase 1 trial, weekly dosing of dinaciclib was explored 
and the recommended dose for further investigation 
was considered to be 12 mg/m2 (resulting in a peak dose 
of approximately 1.2 μmol at 2 hours post-infusion) 
[36]. However, two subsequent clinical trials in which 
combinations of dinaciclib and other chemotherapies 
were administered (both in the metastatic breast cancer 
setting) used either 20 mg/m2 [37] or 50 mg/m2 [38]. Both 
resulted in closure of the studies due to extreme toxicity 
or minimal increases in progression-free survival. Future 
studies of dinaciclib should be combination studies but 
at substantially lower doses that are less likely to cause 
dose-limiting neutropenia, therefore allowing metronomic 
dosing on a weekly or more frequent schedule. 
For the three ongoing clinical trials with publically 
available information about dosing, the doses being used 
are 7 and 9 mg/m2, which should be more tolerable than 
the doses in previous trials. For IBC specifically, our 
radiosensitization data argue that dinaciclib (or future 
CDK2 inhibitors that also downregulate DNA repair 
pathways) may be worthwhile drugs to combine with 
post-mastectomy radiation, particularly for women with 
TN-IBC with substantial residual disease, whom we know 
from retrospective data have a high recurrence risk even 
with comprehensive radiation.
We identified a number of DNA repair genes that 
are significantly inhibited following dinaciclib treatment. 
These corresponding proteins participate in several DNA 
repair pathways, including homologous recombination 
and mismatch repair. Several of these proteins are found 
within the same protein complexes (e.g., FANCA and 
BRCA1, and BRCA1 and BARD1). Depletion of multiple 
components of DNA damage recognition complexes 
and scaffolding proteins is likely sufficient to cause 
functional deficiency in the repair of double-strand breaks 
and interstrand crosslinks. In addition, this multifaceted 
inhibition of repair pathways likely leads to the inability 
to compensate by using alternative repair mechanisms, 
leaving cells with unrepaired DNA damage leading to cell 
death. Because dinaciclib inhibits transcriptional CDKs 
(CDK5 and CDK9), it is possible that the synergy results 
from inhibiting these proteins rather than CDK2 directly, 
a question worth exploring if more specific CDK2, CDK5, 
or CDK9 inhibitors are developed in the future.
We also found that STAT3 transcript levels 
decreased consistently as well as MDC1, which is a known 
target gene that is an important regulator of the ATM-
Chk2 pathway [39]. STAT3 is hyperactivated in IBC, 
as demonstrated by a high incidence of phosphorylated 
STAT3 in tumor tissues and also elevated upstream 
cytokines such as IL6 known to activate this pathway 
[40]. There is a known link between induction of DNA 
damage and activation of CDK5, resulting in STAT3 
phosphorylation and accelerated DNA repair [41]. CDK5 
has also been linked to the DNA damage response via 
phosphorylation of ATM, which is required for ATM 
autophosphorylation and therefore its activity as a damage 
sensor [42]. Together these connections strongly suggest 
the potential for dinaciclib to not only transcriptionally 
regulate DNA damage response proteins but also do so 
via post-transcriptional regulation.
In summary, our data implicate cyclin E as a master 
regulator of a number of pathways important in the 
biology of IBC and resistance to chemotherapy. With these 
pathways in mind, future clinical trials of CDK inhibitors 
may be fruitful areas of development for IBC patients.
MATERIALS AND METHODS
Cell lines
A comprehensive list of the cell lines and their 
growth media is found in Supplementary Table 1. The 
sources of the cells and culture methods are given in the 
supplemental methods. Cells were mycoplasma tested and 
were authenticated upon receipt by short-tandem repeat 
(STR) profiling by the Characterized Cell Line Core 
Facility at The University of Texas MD Anderson Cancer 
Center, and cells from frozen vials were maintained in 
culture no more than 6 weeks. 
Patient samples and chart review
The sample collection, chart review, and data 
analysis for this research were approved by the Institutional 
Review Board of MD Anderson Cancer Center. All patient 
samples were from patients who provided informed 
consent for the banking/use of their tissue for research. 
For outcome analysis, we utilized freedom-from-
recurrence (FFR) as our endpoint, which is a modification 
of the recurrence-free survival endpoint from the guidelines 
of Hudis et al. [43] and was computed as time from 
diagnosis to date of first recurrence (local/regional or 
distant) or to last follow-up (if no recurrence). FFR captures 
only recurrences and does not include deaths as events, 
regardless of cause of death. Patients not experiencing the 
endpoint were censored at last follow-up. 
Cyclin E immunohistochemistry
Cyclin E immunohistochemical analysis was 
performed using optimized conditions as reported in 
Karakas et al. [16]. The primary antibody used was cyclin 
E (C-19, Santa Cruz Biotechnology, sc-198), which was 
diluted 1:1000. The scoring system was described in the 
original publication. 
Western blot analysis
Western blot analyses were performed as previously 
described [44] with the following modifications. The cell 
pellet was lysed in RIPA buffer with a cocktail of protease/
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phosphatase inhibitors (250 µg/ml leupeptin, 250 µg/ml 
aprotinin, 100 µg/ml pepstatin, 1 mM benzamidine, 100 µg/ml 
soybean trypsin inhibitor, 5.0 mM phenylmethylsulfonyl 
fluoride, 50 mM sodium fluoride, and 0.5 mM sodium 
orthovanadate). The primary antibodies used were cyclin 
E (HE12 monoclonal, Santa Cruz Biotechnology, sc-247), 
phospho-CDK2 (Thr160) (polyclonal, Cell Signaling, 
#2561), CDK2 (M2 polyclonal, Santa Cruz Biotechnology, 
sc-163), PARP (polyclonal, Cell signaling #9542), Caspase 
3 (polyclonal, Cell Signaling #9662), Mcl1 (polyclonal, 
Santa Cruz Biotechnology, sc-819) and β-actin (monoclonal, 
Millipore, MAB1501R).
High throughput survival assay (HTSA)
The timeline for this assay is shown as a schematic in 
Figure 3A. The details of assay development are found in 
the Supplementary methods and Supplementary Figure 1.
Apoptosis assay
Apoptosis was quantified using annexin V/
propidium iodide (PI) staining (Life Technologies, Foster 
City, CA, catalogue #V13241) and analyzed by flow 
cytometry according to the manufacturer’s instructions. 
Washed cells were incubated with Alexa-488–conjugated 
annexin V antibody and 1 μg/mL PI for 15 minutes in the 
dark at room temperature. The stained cells were analyzed 
using a FACSCalibur flow cytometer and the CellQuest 
Pro Software, version 6.0.2 (BD Biosciences, Franklin 
Lakes, NJ).
Cell cycle analysis
Nuclear DNA content was analyzed to determine 
the cell cycle phase of treated cells. Cells were harvested 
by trypsinization and fixed in 70% ethanol (in PBS). 
Following fixation and washing with PBS, cells were 
stained with 1 μg/mL PI in buffer overnight. The 
staining buffer consisted of PBS + 0.5% Tween-20 and 
0.5% bovine serum albumin with 20 μg/mL RNase A. 
A FACSCalibur flow cytometer was used with data 
generated using CellQuest Pro Software, version 6.0.2 
(BD Biosciences).
RNA extraction and qRT-PCR
RNA was isolated from cells using the RNeasy mini 
kit (Qiagen, Valencia, CA). After isolation, the RNA was 
ethanol precipitated and resuspended at a concentration 
of 1 μg/μL. cDNA was made using the High Capacity 
First Strand cDNA Synthesis Kit (Life Technologies, 
catalogue #4368814) using 2 μg of total RNA per reaction. 
Quantitative PCR reactions were run using SYBR Green 
PCR master mix (Life Technologies, catalogue #4309155) 
on an AB7500 Fast Real-Time PCR machine. Relative 
expression of each gene was calculated using the ∆∆CT 
method, and GAPDH was used for normalization. Each 
reaction was performed in triplicate, and the experiments 
were repeated in duplicate or triplicate as indicated in the 
figure legends. Sequences of the primers used are found in 
the Supplementary methods.
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